William Blair Downgrades AVEO Pharmaceuticals (AVEO) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Nicolaus Upgrades AVEO Pharmaceuticals (AVEO) to Hold
May 3, 2013 8:37 AM EDTStifel Nicolaus upgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Sell to Hold.
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $2.65 yesterday, with a 52 week range of $2.25-$14.08.... More
RBC Capital Downgrades AVEO Pharmaceuticals (AVEO) to Sector Perform
May 3, 2013 7:15 AM EDTRBC Capital downgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Outperform to Sector Perform.
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $2.65 yesterday, with a 52 week range of $2.25-$14.08.... More
JPMorgan Downgrades AVEO Pharmaceuticals (AVEO) to Neutral
May 2, 2013 2:05 PM EDTJPMorgan downgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Overweight to Neutral.
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $5.26 yesterday, with a 52 week range of $5.07-$14.08.... More
AVEO Oncology (AVEO) Resume Trading, Immediatly Halted
May 2, 2013 1:21 PM EDTAVEO Oncology (NASDAQ: AVEO) resumed trading and was immediately halted on a circuit breaker. Shares down 57%... More
BMO Capital Downgrades AVEO Pharmaceuticals (AVEO) to Underperform
May 2, 2013 12:58 PM EDTBMO Capital downgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Market Perform to Underperform with a price target of $1.00 (from $8.00).
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more... More
AVEO Oncology's (AVEO) Tivozanib Receives Disappointing News from FDA Oncologic Drugs Advisory Committee
May 2, 2013 12:57 PM EDTAVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. today reported that the U.S. Food and Drug Administrations (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled trial (13 to 1, 0 abstentions).
While we are disappointed... More
